Ar­row­head re­ports full Phase 2b da­ta for lipid drug, but Io­n­is is a step ahead: #ACC24

Five months af­ter Ar­row­head Phar­ma­ceu­ti­cals un­veiled topline re­sults for its Phase 2b RNAi can­di­date in a lipid-re­lat­ed dis­ease, the com­pa­ny on Sun­day re­port­ed full da­ta at the Amer­i­can Col­lege of Car­di­ol­o­gy an­nu­al meet­ing.

In the Phase 2b SHAS­TA-2 tri­al of ploza­sir­an in pa­tients with se­vere hy­per­triglyc­eridemia (SHTG), the 25 mg dose de­liv­ered a 58% re­duc­tion in the fast­ing triglyc­eride pri­ma­ry end­point at 48 weeks ver­sus 7% for place­bo (p<0.0001), ac­cord­ing to a com­pa­ny pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER